# US 2026/0097024 A1 · Compositions for and methods to treat, prevent, or reverse metabolic syndrome, type 2 diabetes, and/or cardiovascular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097024 A1
- Document ID: US20260097024A1
- Status: Published application
- Kind: A1
- Application number: 19/352,374
- Filed: 2025-10-07
- Published: 2026-04-09
- Earliest claimed: 2024-10-07
- Applicants: Trimfit for Life, LLC
- Inventors: Roger Catarino; William Kuhne
- Web page: https://patentgrep.com/patent/US20260097024A1

## CPC

- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods and compositions for treating, preventing, reducing the severity of, and/or reversing one or more of obesity, metabolic syndrome, and/or one or more comorbidities thereof. The compositions described herein comprise plant-based DHA and berberine in synergistically effective amounts.

## Claims

### Claim 1

A composition comprising:
a salt of berberine;
docosahexaenoic acid (DHA); and
optionally, one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the salt of berberine is present in the composition in an amount in the range of about 800 mg to about 1,250 mg.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the DHA is present in the composition in an amount in the range of about 150 mg to about 350 mg.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the DHA is present in the composition in an amount of about 200 mg or about 250 mg, and wherein the salt of berberine is present in the composition in an amount of about 1,000 mg.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the salt of berberine is berberine chloride.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition is formulated as an oral dosage.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the oral dosage is a solid form or a liquid form.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the oral dosage is a pill, capsule, or tablet.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the salt of berberine, the docosahexaenoic acid (DHA), or both, are plant-based, mostly plant-based, or derived from one or more plants.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition is over about 95% by weight of the salt of berberine and the docosahexaenoic acid (DHA).

### Claim 11 (depends on 1)

The composition of claim 1, wherein the salt of berberine and the docosahexaenoic acid (DHA) comprise over about 95% by weight of the composition.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the salt of berberine is a pharmaceutically acceptable salt.

### Claim 13

A method, comprising:
administering to a subject in need thereof a composition comprising:
a salt of berberine; and
docosahexaenoic acid (DHA);
wherein the administering is performed to treat, prevent, reduce, or reverse one or more symptoms of one or more disease or condition.

### Claim 14 (depends on 13)

The method of claim 13, wherein the salt of berberine is present in the composition in an amount in the range of about 800 mg to about 1,250 mg.

### Claim 15 (depends on 13)

The method of claim 13, wherein the DHA is present in the composition in an amount in the range of about 150 mg to about 350 mg.

### Claim 16 (depends on 13)

The method of claim 13, wherein the DHA is present in the composition in an amount of about 200 mg or about 250 mg, and wherein the salt of berberine is present in the composition in an amount of about 1,000 mg.

### Claim 17 (depends on 13)

The method of claim 13, wherein the salt of berberine is berberine chloride.

### Claim 18 (depends on 13)

The method of claim 13, wherein the composition is administered at least once per day, such as twice per day, three times per day, four times per day, or more.

### Claim 19 (depends on 13)

The method of claim 13, wherein the salt of berberine and the DHA are present in the pharmaceutical composition in synergistically effective amounts.

### Claim 20 (depends on 13)

The method of claim 13, wherein the composition is administered to the subject for a period of up to 8 weeks.

### Claim 21 (depends on 13)

The method of claim 13, wherein the composition is administered to the subject for a period of at least 4 weeks.

### Claim 22 (depends on 13)

The method of claim 13, wherein the one or more symptoms of one or more disease or condition, or the one or more disease or condition, is obesity.

### Claim 23 (depends on 13)

The method of claim 13, wherein the one or more symptoms of one or more disease or condition, or the one or more disease or condition, is metabolic syndrome.

### Claim 24 (depends on 13)

The method of claim 13, wherein the one or more symptoms of one or more disease or condition, or the one or more disease or condition, is cardiovascular disease.

### Claim 25 (depends on 13)

The method of claim 13, wherein the one or more symptoms of one or more disease or condition, or the one or more disease or condition, is a slowed metabolism.

### Claim 26 (depends on 13)

The method of claim 13, wherein the one or more symptoms of one or more disease or condition, or the one or more disease or condition, is type 2 diabetes.

### Claim 27 (depends on 13)

The method of claim 13, wherein the one or more symptoms of one or more disease or condition is elevated blood sugar.

### Claim 28 (depends on 13)

The method of claim 13, wherein, as a result of the administering, the subject experiences a decrease in body fat percentage, a decrease in body mass, and/or a reduction in waist circumference.

### Claim 29 (depends on 13)

The method of claim 13, wherein as a result of the administering, the subject experiences an increase in lean muscle mass.

### Claim 30 (depends on 13)

The method of claim 13, wherein as a result of the administering, the subject experiences an increased rate of wound healing.

### Claim 31 (depends on 13)

The method of claim 13, wherein as a result of the administering, the subject experiences an increased metabolic rate.

### Claim 32 (depends on 13)

The method of claim 13, wherein the salt of berberine is a pharmaceutically acceptable salt.
